As the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continues to exponentially expand obesity treatment, concerns have arisen regarding their impact on nutrition in people who take them. AACE President, Scott D. Isaacs, MD, FACP, FACE, addresses these concerns in a Medscape article, providing key insights on optimizing patient outcomes through nutrition, education, and support.